Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive
SJ Keam, AJ Wagstaff - Treatments in endocrinology, 2003 - Springer
Ethinylestradiol 30μg/drospirenone 3mg (Yasmin® 1, petibelle®)[EE/DRSP] is a combined
contraceptive pill (CC) for the prevention of pregnancy in women of reproductive age …
contraceptive pill (CC) for the prevention of pregnancy in women of reproductive age …
A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use
J Endrikat, C Gerlinger, K Plettig, J Wessel… - Gynecological …, 2003 - Taylor & Francis
We aimed to evaluate potential correlation between ovarian activity during use of combined
oral contraceptives and the incidence of intermenstrual bleeding. Data from seven …
oral contraceptives and the incidence of intermenstrual bleeding. Data from seven …
[HTML][HTML] Dietary intake of 17α-ethinylestradiol promotes HCC progression in humanized male mice expressing sex hormone-binding globulin
SR Lee, SH Jeong, JH Heo, SL Jo, JW Ko… - International Journal of …, 2021 - mdpi.com
Hepatocellular carcinoma (HCC) is a male-oriented malignancy; its progression is affected
by sex hormones. 17α-ethinylestradiol (EE2) is a synthetic estrogen widely used as an oral …
by sex hormones. 17α-ethinylestradiol (EE2) is a synthetic estrogen widely used as an oral …
[HTML][HTML] The emerging use of the 20-μg oral contraceptive
A Poindexter - Fertility and sterility, 2001 - Elsevier
Objective: To highlight studies that investigated the efficacy, safety, and tolerability of low-
dose oral contraceptives (OCs) containing 20 μg of ethinyl estradiol (EE) and to discuss the …
dose oral contraceptives (OCs) containing 20 μg of ethinyl estradiol (EE) and to discuss the …
Twenty micrograms vs.> 20 μg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials
MF Gallo, K Nanda, DA Grimes, KF Schulz - Contraception, 2005 - Elsevier
Concern about estrogen-related adverse effects has led to progressive reductions in the
estrogen dose in combination oral contraceptives (COCs). This review of randomized …
estrogen dose in combination oral contraceptives (COCs). This review of randomized …
A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20μg and drospirenone 3mg with a 21-day regimen of …
DM Gruber, JC Huber, GB Melis, C Stagg… - Treatments in …, 2006 - Springer
Objective: To compare the cycle control, efficacy, and safety of a new low-dose combined
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg with an …
oral contraceptive containing ethinylestradiol 20μg and drospirenone 3mg with an …
Bleeding pattern with drospirenone 3 mg+ ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ ethinyl estradiol 20 mcg 21 …
L Anttila, M Kunz, J Marr - Contraception, 2009 - Elsevier
BACKGROUND: The study was conducted to compare cycle control, bleeding pattern and
efficacy of two low-dose combined oral contraceptives. STUDY DESIGN: Four hundred fifty …
efficacy of two low-dose combined oral contraceptives. STUDY DESIGN: Four hundred fifty …
Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen
L Hernádi, J Marr, D Trummer, V De Leo, F Petraglia - Contraception, 2009 - Elsevier
OBJECTIVE: The study was conducted to assess the efficacy of a low-dose combined oral
contraceptive (COC) containing drospirenone (drsp) 3 mg/ethinylestradiol (EE) 20 mcg …
contraceptive (COC) containing drospirenone (drsp) 3 mg/ethinylestradiol (EE) 20 mcg …
EE-drospirenone-levomefolate calcium versus EE-drospirenone+ folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment …
K Diefenbach, D Trummer, F Ebert, M Lissy… - … Journal of Women's …, 2013 - Taylor & Francis
Background Adequate folate supplementation in the periconceptional phase is
recommended to reduce the risk of neural tube defects. Oral contraceptives may provide a …
recommended to reduce the risk of neural tube defects. Oral contraceptives may provide a …
A 12-month clinical investigation with a 24-day regimen containing 15 μg ethinylestradiol plus 60 μg gestodene with respect to hemostasis and cycle control
F Fruzzetti, AR Genazzani, C Ricci, F De Negri, C Bersi… - Contraception, 2001 - Elsevier
The effects of a 24-day regimen containing 15 μg ethinyl estradiol (EE) plus 60 μg
gestodene on cycle control and on hemostasis, were evaluated in 58 healthy women (age …
gestodene on cycle control and on hemostasis, were evaluated in 58 healthy women (age …